Towards Rational Prescription of Common Inhaler Medication in the Multimorbid COPD Patient

References

• Divo MJ, Casanova C, Marin JM, et al. COPD comorbidities network. Eur Respir J. 2015;46(3):640. doi:10.1183/09031936.00171614
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Senescence in COPD and its comorbidities. Annu Rev Physiol. 2017;79:517–539. doi:10.1146/annurev-physiol-022516-034314
   PubMed Web of Science ®Google Scholar
• Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA. Epidemiology and impact of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2011;61(582):e12–21. doi:10.3399/bjgp11X548929
   PubMed Web of Science ®Google Scholar
• Buffel Du Vaure C, Ravaud P, Baron G, Barnes C, Gilberg S, Boutron I. Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. BMJ Open. 2016;6(3):e010119. doi:10.1136/bmjopen-2015-010119
   PubMed Web of Science ®Google Scholar
• Tsiligianni IG, Kosmas E, Van der Molen T, Tzanakis N. Managing comorbidity in COPD: a difficult task. Curr Drug Targets. 2013;14(2):158–176. doi:10.2174/1389450111314020004
   PubMed Web of Science ®Google Scholar
• Dorenkamp S, Mesters I, Teijink J, de Bie R. Difficulties of using single-diseased guidelines to treat patients with multiple diseases. Front Public Health. 2015;3:67. doi:10.3389/fpubh.2015.00067
   PubMedGoogle Scholar
• Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109. doi:10.2147/COPD.S54473
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England). 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom. 2018;3:e4. doi:10.1017/gheg.2018.1
   PubMed Web of Science ®Google Scholar
• Chetty U, McLean G, Morrison D, Agur K, Guthrie B, Mercer SW. Chronic obstructive pulmonary disease and comorbidities: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e321–e328. doi:10.3399/bjgp17X690605
   PubMed Web of Science ®Google Scholar
• Mounce LTA, Campbell JL, Henley WE, Tejerina Arreal MC, Porter I, Valderas JM. Predicting incident multimorbidity. Ann Fam Med. 2018;16(4):322–329. doi:10.1370/afm.2271
   PubMed Web of Science ®Google Scholar
• Morrison D, Agur K, Mercer S, Eiras A, Gonzalez-Montalvo JI, Gruffydd-Jones K. Managing multimorbidity in primary care in patients with chronic respiratory conditions. NPJ Prim Care Respir Med. 2016;26:16043. doi:10.1038/npjpcrm.2016.43
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2021 global strategy for prevention, diagnosis and management of COPD; 2021. Available from: https://goldcopd.org/gold-reports/. Accessed April 10, 2021.
   Google Scholar
• Sheridan N, Kenealy T, Salmon E, Rea H, Raphael D, Schmidt-Busby J. Helplessness, self blame and faith may impact on self management in COPD: a qualitative study. Prim Care Respir J. 2011;20(3):307–314. doi:10.4104/pcrj.2011.00035
   PubMedGoogle Scholar
• Sandelowsky H, Hylander I, Krakau I, Modin S, Stallberg B, Nager A. Time pressured deprioritization of COPD in primary care: a qualitative study. Scand J Prim Health Care. 2016;34(1):55–65. doi:10.3109/02813432.2015.1132892
   PubMed Web of Science ®Google Scholar
• Vanfleteren LE, Spruit MA, Franssen FM. Tailoring the approach to multimorbidity in adults with respiratory disease: the NICE guideline. Eur Respir J. 2017;49(2):1601696. doi:10.1183/13993003.01696-2016
   PubMed Web of Science ®Google Scholar
• Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–888. doi:10.2147/COPD.S49621
   PubMed Web of Science ®Google Scholar
• Tényi Á, Vela E, Cano I, et al. Risk and temporal order of disease diagnosis of comorbidities in patients with COPD: a population health perspective. BMJ Open Respir Res. 2018;5(1):e000302. doi:10.1136/bmjresp-2018-000302
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10(1):24. doi:10.1186/s40248-015-0023-2
   PubMedGoogle Scholar
• Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122(4):348–355. doi:10.1016/j.amjmed.2008.09.042
   PubMed Web of Science ®Google Scholar
• Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341–1351. doi:10.1016/S0140-6736(11)60968-9
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respir Int Rev Thorac Dis. 2010;80(2):112–119. doi:10.1159/000281880
   Web of Science ®Google Scholar
• Greulich T, Weist BJD, Koczulla AR, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population. Respir Med. 2017;132:132–138. doi:10.1016/j.rmed.2017.10.007
   PubMed Web of Science ®Google Scholar
• Divo MJ, Celli BR, Poblador-Plou B, et al. Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: evidence from the EpiChron Cohort. PLoS One. 2018;13(2):e0193143. doi:10.1371/journal.pone.0193143
   PubMed Web of Science ®Google Scholar
• Ställberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. doi:10.1038/s41533-018-0101-y
   PubMed Web of Science ®Google Scholar
• Westerik JA, Metting EI, van Boven JF, Tiersma W, Kocks JW, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18(1):31. doi:10.1186/s12931-017-0512-2
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet (London, England). 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Mannino DM, Higuchi K, Yu TC, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138–150. doi:10.1378/chest.14-2434
   PubMed Web of Science ®Google Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Kardos P, Vogelmeier C, Worth H, et al. A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational study. Respir Med. 2017;124:57–64. doi:10.1016/j.rmed.2017.02.007
   PubMed Web of Science ®Google Scholar
• Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–981. doi:10.1164/rccm.201207-1299OC
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Kostikas K, Fang J, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178. doi:10.1186/s12931-019-1130-y
   PubMed Web of Science ®Google Scholar
• Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017;49(5):1601446. doi:10.1183/13993003.01446-2016
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Barrecheguren M, Román-Rodríguez M. Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease. Int J Tuberc Llung Dis. 2015;19(8):992–998. doi:10.5588/ijtld.15.0021
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi:10.1164/rccm.200707-973OC
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. doi:10.1056/NEJMoa1407154
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with Chronic Obstructive Pulmonary Disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. doi:10.1164/rccm.201803-0405OC
   PubMed Web of Science ®Google Scholar
• Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of Pneumonia. Chest. 2015;148(5):1177–1183. doi:10.1378/chest.15-0627
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, Del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. doi:10.1183/09031936.00126814
   PubMed Web of Science ®Google Scholar
• Tsiligianni I, Kampouraki M, Ierodiakonou D, Poulonirakis I, Papadokostakis P. COPD patients’ characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study. Int J Chron Obstruct Pulmon Dis. 2019;14:547–556. doi:10.2147/COPD.S185362
   PubMed Web of Science ®Google Scholar
• Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract. 2014;15:42. doi:10.1186/1471-2296-15-42
   PubMed Web of Science ®Google Scholar
• Sundh J, Aberg J, Hasselgren M, et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. Eur Clin Respir J. 2017;4(1):1409060. doi:10.1080/20018525.2017.1409060
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. doi:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;50(3):1602265. doi:10.1183/13993003.02265-2016
   PubMed Web of Science ®Google Scholar
• Peces-Barba G, Barberà JA, Agustí A, et al. [Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT)]. Arch Bronconeumol. 2008;44(5):271–281. doi:10.1016/S1579-2129(08)60043-9
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• Andreas S. Effects of LAMA/LABA alone and in combination on cardiac safety. Int J Chron Obstruct Pulmon Dis. 2020;15:1931–1933. doi:10.2147/COPD.S246356
   PubMed Web of Science ®Google Scholar
• Chen Y-F, Cheng Y-C, Chou C-H, Chen C-Y, Yu C-J. Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study. BMC Pulm Med. 2019;19(1):233. doi:10.1186/s12890-019-0999-z
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD). Assessment report EMA/330021/2016. 2016.
   Google Scholar
• Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92–100. doi:10.4104/pcrj.2012.00092
   PubMedGoogle Scholar
• Martinez CH, Mannino DM, Divo MJ. Defining COPD-related comorbidities, 2004–2014. Chronic Obstruct Pulmon Dis. 2014;1(1):51–63. doi:10.15326/jcopdf.1.1.2014.0119
   PubMedGoogle Scholar
• Hanlon P, Nicholl BI, Jani BD, et al. Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study. BMJ Open. 2018;8(1):e018404. doi:10.1136/bmjopen-2017-018404
   PubMed Web of Science ®Google Scholar
• Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004;126(1):59–65. doi:10.1378/chest.126.1.59
   PubMed Web of Science ®Google Scholar
• Baarnes CB, Kjeldgaard P, Nielsen M, Miravitlles M, Ulrik CS. Identifying possible asthma-COPD overlap syndrome in patients with a new diagnosis of COPD in primary care. NPJ Prim Care Respir Med. 2017;27:16084. doi:10.1038/npjpcrm.2016.84
   PubMed Web of Science ®Google Scholar
• Nunez A, Sarasate M, Loeb E, Esquinas C, Miravitlles M, Barrecheguren M. Practical guide to the identification and diagnosis of Asthma-COPD Overlap (ACO). Copd. 2019;16:1–7. doi:10.1080/15412555.2019.1575802
   PubMedGoogle Scholar
• Cataldo D, Corhay JL, Derom E, et al. A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2017;12:601–613. doi:10.2147/COPD.S124459
   PubMed Web of Science ®Google Scholar
• Tsiligianni I, Rodriguez MR, Lisspers K, LeeTan T, Infantino A. Call to action: improving primary care for women with COPD. NPJ Prim Care Respir Med. 2017;27(1):11. doi:10.1038/s41533-017-0013-2
   PubMed Web of Science ®Google Scholar
• Langhammer A, Forsmo S, Syversen U. Long-term therapy in COPD: any evidence of adverse effect on bone? Int J Chron Obstruct Pulmon Dis. 2009;4:365–380. doi:10.2147/COPD.S4797
   PubMedGoogle Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699–708. doi:10.1136/thx.2011.160028
   PubMed Web of Science ®Google Scholar
• Trudzinski F, Vogelmeier C, Buhl R, et al. Inhaled steroids and prevalence of osteoporosis in chronic obstructive pulmonary disease: data from the DACCORD cohort. Eur Respir J. 2020;56(Suppl. 64):127.
   Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–1006. doi:10.1016/j.amjmed.2010.06.019
   PubMed Web of Science ®Google Scholar
• Price DB, Russell R, Mares R, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 Diabetes: a historical matched cohort study. PLoS One. 2016;11(9):e0162903. doi:10.1371/journal.pone.0162903
   PubMed Web of Science ®Google Scholar
• Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013;36(10):3009–3014. doi:10.2337/dc12-2197
   PubMed Web of Science ®Google Scholar
• Janson C, Johansson G, Stallberg B, et al. Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respir Res. 2018;19(1):172. doi:10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020;55(6):2000351. doi:10.1183/13993003.00351-2020
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Anzuetao A, Barnes N. Blood eosinophil count and pneumonia riks in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4(9):731-741. doi:10.1016/S2213-2600(16)30148-5
   Web of Science ®Google Scholar
• Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med. 2011;183(5):675–678. doi:10.1164/rccm.201007-1099OC
   PubMed Web of Science ®Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/S0140-6736(17)31222-9
   PubMed Web of Science ®Google Scholar
• Nielsen AO, Pedersen L, Fischer Sode B, Dahl M. β-blocker therapy and risk of Chronic Obstructive Pulmonary Disease – a Danish Nationwide Study of 1.3 million individuals. EClinicalMedicine. 2019;7:21–26. doi:10.1016/j.eclinm.2019.01.004
   PubMedGoogle Scholar
• Tsiligianni I, Hoines K. Rational use of inhaled medications for the patient with COPD and multiple comorbid conditions: guidance for primary care. International Primary Care Respiratory Group desktop helper no 10; 2019. Available from: https://ipcrg.org/sites/ipcrg/files/content/attachments/2020-10-28/IPCRG_DTH10_Multimorbidity_English.pdf.
   Google Scholar
• Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116(4):652–657. doi:10.1016/j.ophtha.2008.12.001
   PubMed Web of Science ®Google Scholar
• Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130(6):1695–1703. doi:10.1378/chest.130.6.1695
   PubMed Web of Science ®Google Scholar
• Vande Griend JP, Linnebur SA. Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia. Ann Pharmacother. 2012;46(9):1245–1249. doi:10.1345/aph.1R282
   PubMed Web of Science ®Google Scholar
• Battaglia S, Cardillo I, Lavorini F, Spatafora M, Scichilone N. Safety considerations of inhaled corticosteroids in the elderly. Drugs Aging. 2014;31(11):787–796. doi:10.1007/s40266-014-0213-1
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419. doi:10.1183/13993003.01359-2015
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41(6):1252–1256. doi:10.1183/09031936.00118912
   PubMed Web of Science ®Google Scholar
• de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007;132(6):1932–1938. doi:10.1378/chest.07-1490
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636–645. doi:10.1016/j.jaci.2012.12.1564
   PubMed Web of Science ®Google Scholar
• Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759–764. doi:10.1136/thorax.57.9.759
   PubMed Web of Science ®Google Scholar
• Contoli M, Pauletti A, Rossi MR, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451. doi:10.1183/13993003.00451-2017
   PubMed Web of Science ®Google Scholar
• Costello RW, Foster JM, Grigg J, et al. The seven stages of man: the role of developmental stage on medication adherence in respiratory diseases. J Allergy Clin Immunol Pract. 2016;4(5):813–820. doi:10.1016/j.jaip.2016.04.002
   PubMed Web of Science ®Google Scholar
• van Schayck O, Wesseling G, Kocks J, Schermer T, Chavannes N. Minder inhalatiecorticosteroïden voor patiënten met COPD. TPO - De Praktijk. 2018;13(2):19–21. doi:10.1007/s12503-018-0023-8
   Google Scholar
• Cataldo D, Derom E, Liistro G, et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. Int J Chron Obstruct Pulmon Dis. 2018;13:2089–2099. doi:10.2147/COPD.S164259
   PubMed Web of Science ®Google Scholar
• Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Safety. 2004;27(10):689–715. doi:10.2165/00002018-200427100-00001
   PubMed Web of Science ®Google Scholar